
Who’s really in charge at Anthropic after the IPO?
Anthropic is going public with a governance maze built for safety, and the people buying its shares will have almost no say over who runs it.
Desk
Coverage tied to Anthropic and Claude.

Anthropic is going public with a governance maze built for safety, and the people buying its shares will have almost no say over who runs it.

Anthropic's prospectus reads partly like a science fiction syllabus, and the strangest risk factors may be the most honest disclosures any AI company has filed.

Anthropic's public promises about curing disease meet the sober reality of its IPO filing, where drug discovery looks slow, costly, and far from guaranteed.

Data centers have become a rare issue that unites angry voters across parties, and the AI industry is learning that money spent on campaigns can't make a neighbor like a server farm.

A one-day, six-agent bake-off shows always-on assistants have finally become useful, but the winner costs $100 a month and every one of them wants the keys to your inbox.

Anthropic's IPO filing says the quiet part plainly: its growth runs on methane-fired power, and the warming that fuel drives is also a cost on its own balance sheet.

Anthropic's S-1 shows a familiar playbook: land with the API, expand into apps, and make leaving harder, which is good business and a growing dependency question for buyers.

Anthropic's prospectus calls AI building AI both a possible existential risk and its biggest competitive edge, and that contradiction is the whole industry in one document.

Anthropic's S-1 asks investors to buy into a mission as much as a business, and the fine print shows how much power, money and risk ride on that request.
Anthropic is handing critical open-source projects free frontier-model security audits, and the catch is that the reports reach maintainers before any human at Anthropic has checked them.
Anthropic's open-source sandbox-runtime puts a fence around agents using the operating system itself, and the real security question is how wide developers leave the gate.

An investment research firm and Anthropic ran a genuinely interesting autonomous protein-design experiment, then sold it as drug discovery. The science got the easy part; the marketing skipped the hard part.